6533b837fe1ef96bd12a2942
RESEARCH PRODUCT
Determinants of high-grade anal intraepithelial lesions in HIV-positive MSM.
Gary M. CliffordJean-damien CombesLaurent SiproudhisJacques ReynesIsabelle EtienneyIsabelle HeardLucie MarchandLionel PirothJean-françois FléjouS. RadenneSébastien HennoAnne LesageIsabelle Poizot-martinIsabelle Poizot-martinsubject
AdultMalemedicine.medical_specialtyBiopsyImmunologyPopulationHIV InfectionsMen who have sex with men03 medical and health sciences0302 clinical medicineCytologyInternal medicineBiopsymedicinePrevalenceImmunology and AllergyAnal cancerHumans030212 general & internal medicineProspective StudiesHomosexuality MaleProspective cohort studyeducationAgededucation.field_of_studyHuman papillomavirus 16medicine.diagnostic_testbusiness.industryPapillomavirus InfectionsAnoscopyMiddle Agedmedicine.diseaseAnus Neoplasms3. Good healthInfectious Diseases030220 oncology & carcinogenesisFemaleFranceSquamous Intraepithelial Lesions of the CervixbusinessAscusdescription
Objective - To assess determinants for histologically proven high-grade anal intraepithelial lesions (hHSIL) in HIV-positive men who have sex with men (MSM), a population at high-risk of HPV-related anal cancer. Design - APACHES is a prospective study of anal HPV and related-lesions in 513 HIV-positive MSM aged at least 35 years in six centres across France. Methods - At baseline, participants underwent high-resolution anoscopy (HRA) with biopsy of suspicious lesions, preceded by anal swabs for liquid-based cytology, p16/Ki67 immunostaining, and HPV DNA. hHSIL diagnosis was established by histopathological review panel consensus, and determinants assessed by logistic regression. Results - Baseline hHSIL prevalence was 10.4% and did not differ significantly by age, sexual behaviour or HIV/immunodeficiency markers. hHSIL prevalence was significantly elevated in participants who smoked (ORadj = 2.6, 95% CI 1.3-5.5) or who, in concurrent anal swabs, had ASCUS/LSIL (3.6, 95% CI 1.4-9.3) or ASC-H/HSIL (22.2, 95% CI 6.8-72.6) cytologic abnormalities, p16/Ki67 dual positivity (3.4, 95% CI 1.5-7.5), or non-HPV16 HR (13.0, 95% CI 1.7-102), but most notably, HPV16 (46.3, 95% CI 6.1-355) infection. Previous diagnosis of low-grade (2.3, 95% CI 1.0-5.4) or high-grade (3.8, 95% CI 1.5-9.9) anal lesion also conveyed higher hHSIL risk. After controlling for patient-specific determinants, there remained significant centre-specific effects, most clearly in higher risk groups (HPV16-positive participants: 31.3% hHSIL in centres A-D versus 5.1% in centres E and F, P < 0.01). Conclusion - Anal cytology and HPV16 infection are potentially useful determinants of hHSIL risk in HIV-positive MSM, but HIV/immunodeficiency-related variables appear not to be. Controlling for patient-specific hHSIL determinants highlights variability in HRA practice across diverse clinical settings and the need for better standardization of this difficult procedure.
year | journal | country | edition | language |
---|---|---|---|---|
2018-10-23 | AIDS (London, England) |